浏览全部资源
扫码关注微信
1.山东医学高等专科学校药学系,济南 250031
2.山东省立第三医院药学部,济南 250031
3.中国海洋大学医药学院,山东 青岛 266000
4.山东省立医院药学部,济南 250031
Published:15 May 2023,
Received:20 November 2022,
Revised:26 February 2023,
扫 描 看 全 文
杨静,张新宇,郑磊等.阿片类药物致便秘与基因多态性的相关性 Δ[J].中国药房,2023,34(09):1104-1108.
YANG Jing,ZHANG Xinyu,ZHENG Lei,et al.Study on the correlation between opioid-induced constipation and gene polymorphism[J].ZHONGGUO YAOFANG,2023,34(09):1104-1108.
杨静,张新宇,郑磊等.阿片类药物致便秘与基因多态性的相关性 Δ[J].中国药房,2023,34(09):1104-1108. DOI: 10.6039/j.issn.1001-0408.2023.09.15.
YANG Jing,ZHANG Xinyu,ZHENG Lei,et al.Study on the correlation between opioid-induced constipation and gene polymorphism[J].ZHONGGUO YAOFANG,2023,34(09):1104-1108. DOI: 10.6039/j.issn.1001-0408.2023.09.15.
目的
2
探讨基因多态性对阿片类药物致便秘的影响。
方法
2
首先通过检索指南、数据库及循证医学资料等筛选出与阿片类药物致便秘相关的目标基因,随后纳入100例接受阿片类药物进行镇痛治疗的癌痛患者,并根据用药后是否出现便秘分为试验组和对照组,每组各50例。利用PCR或荧光原位杂交法对目标基因进行检测;使用SNPStats程序进行Hardy-Weinberg平衡检验、基因多态性与阿片类药物致便秘的相关性分析,采用多因素Logistic回归分析阿片类药物致便秘发生的相关预测因素,绘制受试者工作特征(ROC)曲线分析各预测因素在预测阿片类药物致便秘方面的效能。
结果
2
筛选出的目标基因有
CYP2D6
、
CYP3A5*3
、
ABCB1
、
OPRM1
。基因型检测结果显示,
CYP2D6
(rs1065852、rs1135822、rs16947、rs28371725、rs28371735)、
CYP3A5*3
(058rs776746)、
ABCB1
(062rs1045642)、
OPRM1
(047rs1799971)等位基因频率分布均符合Hardy-Weinberg平衡检验。相关性分析结果显示,试验组患者
CYP3A5*3
(058rs776746,A>G)中的GG、AG型,
OPRM1
(047rs1799971,A>G)中的AA、AG型占比显著高于对照组(
P
<0.05)。多因素Logistic回归分析结果显示,用药时间及
CYP3A5*3、OPRM1
基因多态性可作为患者发生阿片类药物致便秘的预测因素(
P
<0.05)。ROC曲线分析结果显示,用药时间及
CYP3A5*3
、
OPRM1
基因多态性的ROC曲线下面积分别为0.648、0.640、0.670,最佳截断值分别为124.0、0.5、0.5。
结论
2
CYP3A5*3
(058rs776746,A>G)GG、AG型,
OPRM1
(047rs1799971,A>G)AA、AG型与阿片类药物致便秘具有相关性,且上述基因型可能是患者使用阿片类药物致便秘的预测因素,同时还需要关注用药时间较长患者的便秘发生情况。
OBJECTIVE
2
To investigate the effect of gene polymorphism on opioid-induced constipation.
METHODS
2
The target genes related to opioid-induced constipation were screened out through searching guidelines, databases and evidence-based medical data, and then 100 cancer pain patients who received opioid drugs for analgesia were included as the study subjects. According to whether there were adverse effects of constipation after medication or not, they were divided into test group and control group, with 50 cases in each group. The target gene was detected by PCR or fluorescence in situ hybridization. The SNPStats program was used to carry out Hardy-Weinberg balance test and correlation analysis between gene polymorphism and opioid-induced constipation. The multivariate Logistic regression analysis was used to explore the relevant predictive factors of opioid-induced constipation, and receiver operating characteristic (ROC) curve of subjects was drawn to analyze the effectiveness of each predictive factor in predicting opioid-induced constipation.
RESULTS
2
CYP2D6, CYP3A5*3, ABCB1
and
OPRM1
were selected as target genes for detection. The results of genotype detection showed that the frequency distribution of
CYP2D6
(rs1065852, rs1135822, rs16947, rs28371725, rs28371735),
CYP3A5*3
(058rs776746),
ABCB1
(062rs1045642),
OPRM1
(047rs1799971) alleles were consistent with Hardy-Weinberg balance test. The correlation analysis results showed that the proportion of genotype GG and AG in
CYP3A5*3
(058rs776746, A>G) and genotype AA and AG in
OPRM1
(047rs1799971, A>G) of patients was significantly higher in test group than that in the control group (
P
<0.05). Multivariate Logistic regression analysis showed that medication duration,
CYP3A5*3
and
OPRM1
gene polymorphism could be used as predictors of opioid-induced constipation in patients (
P
<0.05). The ROC curve analysis results showed that the areas under the ROC curves for medication duration and
CYP3A5*3
,
OPRM1
gene polymorphism were 0.648, 0.640 and 0.670, respectively, with the optimal cutoff values of 124.0, 0.5 and 0.5, respectively.
CONCLUSIONS
2
Genotype GG and AG in
CYP3A5*3
(058rs776746,A>G) and genotype AA and AG in
OPRM1
(047rs1799971,A>G) are associated with opioid-induced constipation, which are expected to become clinical predictors of opioid-induced constipation, and more attention should be paid to the occurrence of constipation in patients who have been taking opioids for a long time.
阿片类药物基因多态性药物不良反应便秘个体化用药
gene polymorphismadverse drug reactionsconstipationindividualized medication
王玥,蒋葵. 阿片类药物引起的便秘病理机制及治疗进展[J]. 中国肿瘤临床,2021,48(16):852-857.
SIEGEL R L,MILLER K D,JEMAL A. Cancer statistics,2015[J]. CA A Cancer J Clin,2015,65(1):5-29.
PUSPITASARI A,IKAWATI Z,SWASTHIKAWATI S, et al. High frequency of the opioid receptor µ-1 (OPRM1) A118G polymorphism,an opioid drug therapy related gene,in the Indonesian population[J]. Curr Pharmaco- genomics Person Med,2019,17(1):64-69.
黄仟,温泽淮. 倡议建立协调统一的药物不良反应因果关系评价标准[J]. 中国新药杂志,2021,30(12):1132-1136.
MA J,LI W Y,CHAI Q,et al. Correlation of P2RX7 gene rs1718125 polymorphism with postoperative fentanyl anal- gesia in patients with lung cancer[J]. Medicine (Baltimore),2019,98(7):e14445.
PALADA V,KAUNISTO M A,KALSO E. Genetics and genomics in postoperative pain and analgesia[J]. Curr Opin Anaesthesiol,2018,31(5):569-574.
RUANO G,KOST J A. Fundamental considerations for genetically-guided pain management with opioids based on CYP2D6 and OPRM1 polymorphisms[J]. Pain Physician,2018,21(6):E611-E621.
WANG L Z,WEI C N,XIAO F,et al. Influences of COMT rs4680 and OPRM1 rs1799971 polymorphisms on chronic postsurgical pain,acute pain,and analgesic consumption after elective cesarean delivery[J]. Clin J Pain,2019,35(1):31-36.
KHALIL H,SEREIKA S M,DAI F,et al. OPRM1 and COMT gene-gene interaction is associated with postoperative pain and opioid consumption after orthopedic trauma[J]. Biol Res Nurs,2017,19(2):170-179.
HAJJ A,HALEPIAN L,OSTA N E,et al. OPRM1 c.118A>G polymorphism and duration of morphine treatment associated with morphine doses and quality-of-life in palliative cancer pain settings[J]. Int J Mol Sci,2017,18(4):669.
GRAY K,ADHIKARY S D,JANICKI P. Pharmacogeno- mics of analgesics in anesthesia practice:a current update of literature[J]. J Anaesthesiol Clin Pharmacol,2018,34(2):155-160.
SIA A T,LIM Y,LIM E C,et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia[J]. Anesthesiology,2008,109(3):520-526.
杨菁,郑斌,曾晓芳,等. 亚洲人群OPRM1基因rs1799971多态性和术后阿片类药物使用剂量关系的Meta分析[J]. 中国循证医学杂志,2016,16(12):1388-1393.
SADHASIVAM S,CHIDAMBARAN V,ZHANG X, et al. Opioid-induced respiratory depression:ABCB1 transporter pharmacogenetics[J]. Pharmacogenomics J,2015,15(2):119-126.
OLESEN A E,SATO H,NIELSEN L M,et al. The genetic influences on oxycodone response characteristics in human experimental pain[J]. Fundam Clin Pharmacol,2015,29(4):417-425.
CREWS K R,MONTE A A,HUDDART R,et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6,OPRM1,and COMT genotypes and select opioid therapy[J]. Clin Pharmacol Ther,2021,110(4):888-896.
PACKIASABAPATHY S,ARULDHAS B W,HORN N,et al. Pharmacogenomics of methadone:a narrative review of the literature[J]. Pharmacogenomics,2020,21(12):871-887.
NAITO T, TAKASHINA Y, YAMAMOTO K, et al. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone[J]. J Clin Pharmacol,2011,51(11):1529-1538.
MURPHY L, BRANDS B, GRANT D, et al. Exploring the use of extended release opioids at shortened dosing intervals in people with chronic pain and high risk medi- cation or substance use[J]. Int J Clin Pharm,2021,43(2):404-410.
0
Views
5
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution